相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations
J. Mazieres et al.
ANNALS OF ONCOLOGY (2020)
KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
Misako Nagasaka et al.
CANCER TREATMENT REVIEWS (2020)
A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients
Giorgio Scagliotti et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
Robert C. Doebele et al.
LANCET ONCOLOGY (2020)
Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors
Jayesh Desai et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping
Ravi Salgia et al.
CANCER TREATMENT REVIEWS (2020)
The real-world experience with nivolumab in previously treated patients with advanced non-small cell lung cancer from a cancer center in India
Waseem Abbas et al.
SOUTH ASIAN JOURNAL OF CANCER (2020)
HER2: defining a Neu target in non-small-cell lung cancer
S. Ekman
ANNALS OF ONCOLOGY (2019)
Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer
J. Gao et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2019)
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations
Martin H. Voss et al.
CLINICAL CANCER RESEARCH (2019)
Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice
Philippe Jamme et al.
CLINICAL LUNG CANCER (2019)
Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers
Konrad Pawelczyk et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP)
Rafal Dziadziuszko et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer
Aiwu Ruth He et al.
ONCOLOGIST (2019)
Outcome Differences Between First- and Second-generation EGFR Inhibitors in Advanced EGFR Mutated NSCLC in a Large Population-based Cohort
Sally C. Lau et al.
CLINICAL LUNG CANCER (2019)
ALK rearrangements: Biology, detection and opportunities of therapy in non-small cell lung cancer
Gina Rosas et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
A phase I study of BOS172738 in patients with advanced solid tumors with RET gene alterations including non-small cell lung cancer and medullary thyroid cancer.
Patrick Schoffski et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A phase I/II multiple expansion cohort trial of MRTX849 in patients with advanced solid tumors with KRAS G12C mutation.
Kyriakos P. Papadopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Early clinical experience with the pan-FGFR inhibitor rogaratinib in patients with non-small cell lung cancer selected based on FGFR mRNA expression levels.
Markus Joerger et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Emerging therapies for non-small cell lung cancer
Chao Zhang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors
Tessa A. Morris et al.
DRUGS (2019)
SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)
Charu Aggarwal et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance
Melissa Dolan et al.
PLOS ONE (2019)
A Selective FGFR inhibitor AZD4547 suppresses RANKL/M-CSF/OPG-dependent ostoclastogenesis and breast cancer growth in the metastatic bone microenvironment
Jinho Kang et al.
SCIENTIFIC REPORTS (2019)
Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
Eric Santoni-Rugiu et al.
CANCERS (2019)
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
Gwo-Fuang Ho et al.
BMC CANCER (2019)
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Alessandro Leonetti et al.
BRITISH JOURNAL OF CANCER (2019)
Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial
Lorenza Landi et al.
CLINICAL CANCER RESEARCH (2019)
Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma
Bradley A. McGregor et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)
Capmatinib for the treatment of non-small cell lung cancer
Johan Filip Vansteenkiste et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2019)
Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer A Review
Kathryn C. Arbour et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Akintunde Akinleye et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma
Toyoaki Hida et al.
LUNG CANCER (2019)
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
Narjust Duma et al.
MAYO CLINIC PROCEEDINGS (2019)
TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations
Hibiki Udagawa et al.
MOLECULAR CANCER RESEARCH (2019)
Targeted Therapy For RET-Rearranged Non-Small Cell Lung Cancer: Clinical Development And Future Directions
Christoph Jakob Ackermann et al.
ONCOTARGETS AND THERAPY (2019)
Response and acquired resistance to savolitinib in a patient with pulmonary sarcomatoid carcinoma harboring MET exon 14 skipping mutation: a case report
Sen Han et al.
ONCOTARGETS AND THERAPY (2019)
Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives
Daniele Lavacchi et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2019)
Targeting Oncogenic BRAF: Past, Present, and Future
Aubhishek Zaman et al.
CANCERS (2019)
BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale
Jillian Wilhelmina Paulina Bracht et al.
CANCERS (2019)
Epigenetic Mechanisms of Escape from BRAF Oncogene Dependency
Mehwish Khaliq et al.
CANCERS (2019)
444PDSafety and preliminary clinical activity of repotrectinib in patients with advanced ROS1/TRK fusion-positive solid tumors (TRIDENT-1 study)
A Drilon et al.
ANNALS OF ONCOLOGY (2019)
Tepotinib in NSCLC patients with METex14 mutations: interim results from the phase II VISION study
Hiroshi Sakai et al.
ANNALS OF ONCOLOGY (2019)
363OTreatment with pralsetinib (formerly BLU-667), a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC)
D H Lee et al.
ANNALS OF ONCOLOGY (2019)
Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer
A. Amatu et al.
ANNALS OF ONCOLOGY (2019)
MEK Inhibitors in Lung Cancer-You Can Teach an Old Drug New Tricks
Jonathan J. Havel
CANCER RESEARCH (2019)
Phase 1 Study of Safety, Tolerability, PK and Efficacy of AMG 510, a Novel KRASG12C Inhibitor, Evaluated in NSCLC
R. Govindan et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
A Multicenter, Double-Blind, Randomized, Controlled Study of Bintrafusp Alfa (M7824) in Unresectable Stage III NSCLC
E. Vokes et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Phase II Single Arm Study of CABozantinib in Non-Small Cell Lung Cancer Patients with MET Deregulation (CABinMET)
M. D'Arcangelo et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma
Maria Colombino et al.
BMC PULMONARY MEDICINE (2019)
HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib
Y. Wang et al.
ANNALS OF ONCOLOGY (2019)
Brigatinib: Novel ALK Inhibitor for Non-Small-Cell Lung Cancer
Sara A. Spencer et al.
ANNALS OF PHARMACOTHERAPY (2019)
TAS-120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure
Maria Kalyukina et al.
CHEMMEDCHEM (2019)
Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors
David S. Hong et al.
CLINICAL CANCER RESEARCH (2019)
Necitumumab for the treatment of advanced non-small-cell lung cancer
Asuncion Diaz-Serrano et al.
FUTURE ONCOLOGY (2019)
Anti-mitotic therapies in cancer
Julia Tischer et al.
JOURNAL OF CELL BIOLOGY (2019)
Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy
Zuan-Fu Lim et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study
Myung-Ju Ahn et al.
LANCET ONCOLOGY (2019)
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial
Alice T. Shaw et al.
LANCET ONCOLOGY (2019)
Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies
Fiona H. Tan et al.
ONCOTARGETS AND THERAPY (2019)
CDK4/6 inhibition alone and in combination for non-small cell lung cancer
Jose Pacheco et al.
Oncotarget (2019)
Mechanisms of resistance to pemetrexed in non-small cell lung cancer
Jiaqi Liang et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2019)
Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience
Angela Botticella et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2019)
Polytherapy and Targeted Cancer Drug Resistance
Nilanjana Chatterjee et al.
TRENDS IN CANCER (2019)
Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers
Solange Peters et al.
CLINICAL CANCER RESEARCH (2019)
Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
Simon Vyse et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
Pembrolizumab for the treatment of nonsmall cell lung cancer: Current status and future directions
Qin Qin et al.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS (2019)
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
Min Yuan et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
MEK inhibitors under development for treatment of non-small-cell lung cancer
Chul Kim et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
Alexander Drilon et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Tumour heterogeneity and resistance to cancer therapies
Ibiayi Dagogo-Jack et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer
D. F. Gerber et al.
ANNALS OF ONCOLOGY (2018)
A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer
Amita Patnaik et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Mechanisms of Resistance to PD-1 and PD-L1 Blockade
Theodore S. Nowicki et al.
CANCER JOURNAL (2018)
HER2 Deregulation in Lung Cancer: Right Time to Adopt an Orphan?
Federico Cappuzzo et al.
CLINICAL CANCER RESEARCH (2018)
Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
Leora Horn et al.
CLINICAL CANCER RESEARCH (2018)
ALK inhibitors, resistance development, clinical trials
J. M. Rothenstein et al.
CURRENT ONCOLOGY (2018)
Antiangiogenic therapies in non-small-cell lung cancer
A. Alshangiti et al.
CURRENT ONCOLOGY (2018)
The side effects of platinum-based chemotherapy drugs: a review for chemists
Rabbab Oun et al.
DALTON TRANSACTIONS (2018)
Glutathione metabolism in cancer progression and treatment resistance
Ankita Bansal et al.
JOURNAL OF CELL BIOLOGY (2018)
KRAS-Mutant non-small cell lung cancer: From biology to therapy
Irene Ferrer et al.
LUNG CANCER (2018)
Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities
Yazhuo Zhang et al.
MOLECULAR CANCER (2018)
TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations
Shinichi Hasako et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Precision Targeted Therapy with BLU-667 for RET-Driven Cancers
Vivek Subbiah et al.
CANCER DISCOVERY (2018)
BRAF inhibitors in metastatic non-small cell lung cancer
Georgia Anguera et al.
JOURNAL OF THORACIC DISEASE (2018)
Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
Dazhi Liu et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2018)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D. Planchard et al.
ANNALS OF ONCOLOGY (2018)
Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial.
D. Ross Camidge et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Histone deacetylase 6 in cancer
Ting Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
The roles of metallothioneins in carcinogenesis
Manfei Si et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study
Fabrice Barlesi et al.
LANCET ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors
Kartik Sehgal et al.
TRANSLATIONAL CANCER RESEARCH (2018)
Drug Resistance in Non-Small Cell Lung Cancer: A Potential for NOTCH Targeting?
Venus Sosa Iglesias et al.
FRONTIERS IN ONCOLOGY (2018)
1162PCemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2)
V Moreno et al.
ANNALS OF ONCOLOGY (2018)
Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions
Z. Piotrowska et al.
ANNALS OF ONCOLOGY (2018)
1497PJNJ-61186372 (JNJ-372), an EGFR-cMET bispecific antibody, in advanced non-small cell lung cancer (NSCLC): An update on phase I results
B C Cho et al.
ANNALS OF ONCOLOGY (2018)
FGFR genes mutation is an independent prognostic factor and associated with lymph node metastasis in squamous non-small cell lung cancer
Jing Jing Li et al.
CANCER BIOLOGY & THERAPY (2018)
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Benjamin J. Solomon et al.
LANCET ONCOLOGY (2018)
Sunitinib-suppressed miR-452-5p facilitates renal cancer cell invasion and metastasis through modulating SMAD4/SMAD7 signals
Wei Zhai et al.
MOLECULAR CANCER (2018)
NTRK fusion-positive cancers and TRK inhibitor therapy
Emiliano Cocco et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition
Priya K. Gopalan et al.
Oncotarget (2018)
Sitravatinib potentiates immune checkpoint blockade in refractory cancer models
Wenting Du et al.
JCI INSIGHT (2018)
A Phase II Trial of Poziotinib in EGFR and HER2 exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC)
J. Heymach et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Personalized therapy for lung cancer: Striking a moving target
Suchita Pakkala et al.
JCI INSIGHT (2018)
Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience
Arjun Khunger et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2018)
Updated Results of Phase 1 Study of DS-8201a in HER2-Expressing or - Mutated Advanced Non-Small-Cell Lung Cancer
J. Tsurutani et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Safety, PK, and Preliminary Antitumor Activity of the Oral EGFR/HER2 Exon 20 Inhibitor TAK-788 in NSCLC
J. Neal et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET Fusion plus Non-Small Cell Lung Cancer
G. Oxnard et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
TAK-788 is a Novel and Potent Tyrosine Kinase Inhibitor with Selective Activity Against EGFR/HER2
J. Chouitar et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
A Phase I/Ib Study of Binimetinib (MEK162), a MEK Inhibitor Plus Carboplatin/Pemetrexed in Non-Squamous NSCLC
D. Graham et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
A Phase 2 Study of DS-8201a in HER2-Overexpressing or -Mutated Advanced Non-Small-Cell Lung Cancer
P. Janne et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
The biology and management of non-small cell lung cancer
Roy S. Herbst et al.
NATURE (2018)
Role of immune-checkpoint inhibitors in lung cancer
Prantesh Jain et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2018)
EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas
Susan E. Jorge et al.
CLINICAL CANCER RESEARCH (2018)
Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial
S. -H. Lee et al.
ANNALS OF ONCOLOGY (2017)
Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations
Gang G. Li et al.
CLINICAL CANCER RESEARCH (2017)
Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application
Young Kwang Chae et al.
ONCOTARGET (2017)
Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer
Erika Rijavec et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
Selumetinib for the treatment of non-small cell lung cancer
Francesca Casaluce et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
Lucia Nogova et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A Phase Ib Study of the Combination of Afatinib and Ruxolitinib in EGFR Mutant NSCLC Progressed on EGFR-TKI: An Updated Analysis
J. S. Park et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Tedopi vs Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Advanced NSCLC Patients in a Phase 3, Randomized Trial: ATALANTE-1
Benjamin Besse et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Preliminary Results of a Phase II Study about the Efficacy and Safety of Pyrotinib in Patients with HER2 Mutant Advanced NSCLC
Shengxiang Ren et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer
Martin Reck et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Neratinib Temsirolimus in HER2-Mutant Lung Cancers: An International, Randomized Phase II Study
Leena Gandhi et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Intracranial Activity of Cabozantinib in MET Exon 14-Positive NSCLC with Brain Metastases
Samuel J. Klempner et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Recent Advances in Targeting ROS1 in Lung Cancer
Jessica J. Lin et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Tesevatinib in NSCLC Patients with EGFR Activating Mutations and Brain Metastases (BM) or Leptomeningeal Metastases (LM)
Davic Berz et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2017)
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
Alice T. Shaw et al.
LANCET ONCOLOGY (2017)
Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer
Raffaele Califano et al.
LUNG CANCER (2017)
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable
Thanyanan Reungwetwattana et al.
LUNG CANCER (2017)
Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence
Biagio Ricciuti et al.
MEDICAL ONCOLOGY (2017)
Intra-tumor heterogeneity from a cancer stem cell perspective
Pramudita R. Prasetyanti et al.
MOLECULAR CANCER (2017)
ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2017)
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
Alexander Drilon et al.
CANCER DISCOVERY (2017)
Targeting ALK: Precision Medicine Takes on Drug Resistance
Jessica J. Lin et al.
CANCER DISCOVERY (2017)
A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer
Robin M. J. M. van Geel et al.
CANCER DISCOVERY (2017)
Aberrant Signaling through the HER2-ERK1/2 Pathway is Predictive of Reduced Disease-Free and Overall Survival in Early Stage Non- Small Cell Lung Cancer (NSCLC) Patients
Marianna Scrima et al.
JOURNAL OF CANCER (2017)
Optimal pembrolizumab dosing for non-small cell lung cancer: further studies still needed
Hai-Yan Tu et al.
JOURNAL OF THORACIC DISEASE (2017)
Activating HER2 mutations as emerging targets in multiple solid cancers
Claire M. Connell et al.
ESMO OPEN (2017)
Precision cancer therapy is impacted by oncogene-dependent epigenome remodeling
Feng Liu et al.
NPJ PRECISION ONCOLOGY (2017)
Sym015: A Highly Efficacious Antibody Mixture against MET-Amplified Tumors
Thomas Tuxen Poulsen et al.
CLINICAL CANCER RESEARCH (2017)
Palbociclib, a selective CDK4/6 inhibitor, enhances the effect of selumetinib in RAS-driven non-small cell lung cancer
Jianya Zhou et al.
CANCER LETTERS (2017)
HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium
Rathi N. Pillai et al.
CANCER (2017)
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models
Lars D. Engstrom et al.
CLINICAL CANCER RESEARCH (2017)
Patient Experience of Symptoms and Side Effects when Treated with Osimertinib for Advanced Non-Small-Cell Lung Cancer: A Qualitative Interview Substudy
Anna Ryden et al.
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH (2017)
Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer
Anna F. Farago et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2017)
Mechanisms of Primary Drug Resistance in FGFR1-Amplified Lung Cancer
Florian Malchers et al.
CLINICAL CANCER RESEARCH (2017)
RAS Proteins and Their Regulators in Human Disease
Dhirendra K. Simanshu et al.
CELL (2017)
A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors
A. W. Tolcher et al.
ANNALS OF ONCOLOGY (2016)
Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape
K. A. Olaussen et al.
ANNALS OF ONCOLOGY (2016)
Crizotinib resistance: implications for therapeutic strategies
I. Dagogo-Jack et al.
ANNALS OF ONCOLOGY (2016)
Fibroblast Growth Factor Receptor 1 Gene Amplification in Nonsmall Cell Lung Cancer
Jian-Long Miao et al.
CHINESE MEDICAL JOURNAL (2016)
Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications
A. Quintanal-Villalonga et al.
DISEASE MARKERS (2016)
The development of LOXO-195, a second generation TRK kinase inhibitor that overcomes acquired resistance to 1st generation inhibitors observed in patients with TRK-fusion cancers
J. Blake et al.
EUROPEAN JOURNAL OF CANCER (2016)
Exon Skipping in the RET Gene Encodes Novel Isoforms That Differentially Regulate RET Protein Signal Transduction
Nicole A. Gabreski et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Clinicopathologic Features of Advanced Squamous NSCLC
Mark A. Socinski et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers
Bob T. Li et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
FGFR Signaling as a Target for Lung Cancer Therapy
Arpita Desai et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
Heather Donaghy
MABS (2016)
Targeting the KRAS Pathway in Non-Small Cell Lung Cancer
Pascale Tomasini et al.
ONCOLOGIST (2016)
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
Justin F. Gainor et al.
CANCER DISCOVERY (2016)
Nintedanib in NSCLC: evidence to date and place in therapy
Giuseppe Bronte et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2016)
Non-small cell lung cancer: current treatment and future advances
Cecilia Zappa et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2016)
Mechanisms of resistance to EGFR-targeted drugs: lung cancer
Floriana Morgillo et al.
ESMO OPEN (2016)
Acquired resistance to immunotherapy and future challenges
Nicholas P. Restifo et al.
NATURE REVIEWS CANCER (2016)
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)
G. R. Blumenschein et al.
ANNALS OF ONCOLOGY (2015)
Predictive value of STMN1 gene promoter polymorphism (-2166T>C) in patients with advanced NSCLC treated with the combination of platinum compounds and vinorelbine
Radosaw Mlak et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Lung Cancer in the Era of Precision Medicine
Katerina Politi et al.
CLINICAL CANCER RESEARCH (2015)
Intratumoral Heterogeneity: From Diversity Comes Resistance
Ariel Pribluda et al.
CLINICAL CANCER RESEARCH (2015)
Staging of lung cancer: the role of noninvasive, minimally invasive and invasive techniques
Georgios Stamatis
EUROPEAN RESPIRATORY JOURNAL (2015)
Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies
Elizabeth E. Evans et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Nivolumab in NSCLC: latest evidence and clinical potential
Raghav Sundar et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2015)
TRKing Down an Old Oncogene in a New Era of Targeted Therapy
Aria Vaishnavi et al.
CANCER DISCOVERY (2015)
Managing treatment-related adverse events associated with Alk inhibitors
J. M. Rothenstein et al.
CURRENT ONCOLOGY (2014)
Reproducibility of Histopathological Diagnosis in Poorly Differentiated NSCLC An International Multiobserver Study
Erik Thunnissen et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Programmed death ligand-1 expression in non-small cell lung cancer
Vamsidhar Velcheti et al.
LABORATORY INVESTIGATION (2014)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
Lung Cancer Screening with Low-Dose Computed Tomography
Caroline Chiles
RADIOLOGIC CLINICS OF NORTH AMERICA (2014)
Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors
Ravi Salgia
CANCER MEDICINE (2014)
Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas
Alexis B. Cortot et al.
EUROPEAN RESPIRATORY REVIEW (2014)
DNA repair pathways and their therapeutic potential in lung cancer
Joshua T. Burgess et al.
LUNG CANCER MANAGEMENT (2014)
Ins and Outs of Kinase DFG Motifs
Daniel K. Treiber et al.
CHEMISTRY & BIOLOGY (2013)
Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer
Parvin F. Peddi et al.
FUTURE ONCOLOGY (2013)
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells
Erika Martinelli et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
The role of βIII-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy
Kyoichi Kaira et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2013)
MEK and the inhibitors: from bench to bedside
Akintunde Akinleye et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics
Maria E. Arcila et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Novel Targets in Non-Small Cell Lung Cancer: ROS1 and RET Fusions
Justin F. Gainor et al.
ONCOLOGIST (2013)
Role of Glutathione in Cancer Progression and Chemoresistance
Nicola Traverso et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2013)
The genetics and biology of KRAS in lung cancer
Peter M. K. Westcott et al.
CHINESE JOURNAL OF CANCER (2013)
Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-targeted therapy for advanced non-small cell lung cancer: Molecular and clinical aspects
Isamu Okamoto et al.
CANCER SCIENCE (2012)
Crizotinib for ALK-Rearranged Non-Small Cell Lung Cancer: A New Targeted Therapy for a New Target
Leena Gandhi et al.
CLINICAL CANCER RESEARCH (2012)
Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis
John Mascarenhas et al.
CLINICAL CANCER RESEARCH (2012)
Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations
Natasha Rekhtman et al.
CLINICAL CANCER RESEARCH (2012)
Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
Nathan T. Ihle et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications
Hiroyuki Yasuda et al.
LANCET ONCOLOGY (2012)
Comprehensive genomic characterization of squamous cell lung cancers
Peter S. Hammerman et al.
NATURE (2012)
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Julian R. Molina et al.
MAYO CLINIC PROCEEDINGS (2012)
Epithelial Mesenchymal Transition in Drug Resistance and Metastasis of Lung Cancer
Fariz Nurwidya et al.
CANCER RESEARCH AND TREATMENT (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer
M. C. Garassino et al.
ANNALS OF ONCOLOGY (2011)
Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors
Christine M. Lovly et al.
CANCER RESEARCH (2011)
TP53 Mutations in Nonsmall Cell Lung Cancer
Akira Mogi et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2011)
Lung Resistance Protein and Multidrug Resistance Protein in Non-small Cell Lung Cancer and Their Clinical Significance
Z. J. Chen et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2011)
The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo
Jun Chen et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC
Alex Chang
LUNG CANCER (2011)
Safety and Efficacy of Vinorelbine in the Treatment of Non-Small Cell Lung Cancer
Bryan A. Faller et al.
CLINICAL MEDICINE INSIGHTS-ONCOLOGY (2011)
Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer
Helen J. Ross et al.
CLINICAL CANCER RESEARCH (2010)
A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
Eric B. Haura et al.
CLINICAL CANCER RESEARCH (2010)
Side-Effects of Long-Term Administration of Erlotinib in Patients with Non-small Cell Lung Cancer
Annemarie Becker et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Platelet-Derived Growth Factor (PDGF)/PDGF Receptors (PDGFR) Axis as Target for Antitumor and Antiangiogenic Therapy
Marius Raica et al.
PHARMACEUTICALS (2010)
Semaphorin signaling in cancer cells and in cells of the tumor microenvironment - two sides of a coin
Lorena Capparuccia et al.
JOURNAL OF CELL SCIENCE (2009)
The basics of epithelial-mesenchymal transition
Raghu Kalluri et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Neil L. Spector et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine
J. Souglakos et al.
BRITISH JOURNAL OF CANCER (2008)
Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: A systematic review of randomized controlled trials
Anand Rajeswaran et al.
LUNG CANCER (2008)
Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer
Emmanuelle Wesarg et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Looking at drug resistance mechanisms for microtubule interacting drugs: Does TUBB3 work?
Cristiano Ferlini et al.
CURRENT CANCER DRUG TARGETS (2007)
Radiation-enhanced vascular targeting of human lung cancers in mice with a monoclonal antibody that binds anionic phospholipids
Jin He et al.
CLINICAL CANCER RESEARCH (2007)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Docetaxel in non-small cell lung cancer - Impact on quality of life and pharmacoeconomics
Leora Horn et al.
DRUGS & AGING (2007)
Epidermal growth factor receptor mutations in lung cancer
Sreenath V. Sharma et al.
NATURE REVIEWS CANCER (2007)
A review of topoisomerase inhibition in lung cancer
Hatim Chhatriwala et al.
CANCER BIOLOGY & THERAPY (2006)
RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer
Gerold Bepler et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Gefitinib: an adverse effects profile
Robert J. Cersosimo
EXPERT OPINION ON DRUG SAFETY (2006)
Biology of platelet-derived growth factor and its involvement in disease
Ricardo H. Alvarez et al.
MAYO CLINIC PROCEEDINGS (2006)
Treatment of advanced non-small cell lung cancer
L De Petris et al.
ANNALS OF ONCOLOGY (2006)
Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface
JP Dawson et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications
W Berger et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2005)
A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in mice
XM Huang et al.
CANCER RESEARCH (2005)
Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis
M Presta et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2005)
Somatic mutations of the HER2 kinase domain in lung adenocarcinomas
H Shigematsu et al.
CANCER RESEARCH (2005)
Pemetrexed: A multitargeted antifolate
KD Rollins et al.
CLINICAL THERAPEUTICS (2005)
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
AH Schinkel et al.
ADVANCED DRUG DELIVERY REVIEWS (2003)
Weekly paclitaxel in advanced non-small cell lung cancer
AYC Chang et al.
SEMINARS IN ONCOLOGY (2001)
A family of drug transporters: The multidrug resistance-associated proteins
P Borst et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein
ZE Sauna et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
分享论文
